Credit Suisse analyst Martin Auster maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) yesterday and set a price target of $156. The company’s shares closed yesterday at $121.49.
According to TipRanks.com, Auster is a 1-star analyst with an average return of -4.0% and a 28.6% success rate. Auster covers the Healthcare sector, focusing on stocks such as Solid Biosciences Llc, PTC Therapeutics, and AnaptysBio Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alexion Pharmaceuticals with a $165.21 average price target, which is a 36.0% upside from current levels. In a report issued on October 11, Morgan Stanley also maintained a Buy rating on the stock with a $165 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $144.91 and a one-year low of $102.10. Currently, Alexion Pharmaceuticals has an average volume of 1.45M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma.
